GlassScriptPhysician profile
Daniel A Espinosa
NPI 1235585381
$2,475.20
in general payments reported to CMS, 2019-2025
23 companies · $849 in 2025
The $849 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.78 · 2021: $204 · 2022: $216 · 2023: $366 · 2024: $823 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $536.30 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $510.13 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $310.08 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $154.17 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $137.22 | 2022-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $135.89 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $114.49 | 2022-2025 | |
| Glaxosmithkline, LLC. | $95.83 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $88.48 | 2023-2025 | |
| Nevro Corp. | $74.16 | 2023-2024 | Senza |
| Shield Therapeutics INC | $53.44 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.62 | 2022-2025 | Jardiance |
| Urogen Pharma, INC. | $29.99 | 2025 | |
| Merck Sharp & Dohme LLC | $29.30 | 2021 | |
| Ani Pharmaceuticals, INC. | $24.50 | 2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $24.14 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $22.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.20 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $18.43 | 2022 | |
| Melinta Therapeutics, LLC | $17.78 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.58 | 2022 | |
| Esperion Therapeutics, INC. | $15.55 | 2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $13.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Espinosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.